Literature DB >> 9655540

Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy.

W C Koch1, J H Harger, B Barnstein, S P Adler.   

Abstract

OBJECTIVE: To define the intrauterine viral transmission rate during primary maternal parvovirus B19 infection and identify factors that may influence this rate.
METHODS: Forty-three pregnant women at two medical centers were identified with a primary B19 infection and followed to delivery. At delivery maternal and infant (umbilical cord) blood was obtained for B19 serologic and virologic PCR testing.
RESULTS: All of the women delivered healthy infants at term and none was hydropic. Overall 22 (51%) of the 43 infants had some evidence of a congenital B19 infection. B19-specific IgM was detected in 11 infants at delivery, B19 IgA was detected in 10 and B19 DNA was detectable by PCR in 11 infants. One infant was negative at birth but became positive for IgM, IgA and PCR at 6 weeks of age. No association was found between the likelihood of intrauterine infection and: maternal age; symptomatic maternal infection; method of delivery; maternal IgG titer at delivery; maternal IgG avidity at delivery; or maternal viremia at delivery. Intrauterine infection was associated with maternal IgM positivity at delivery; this association may have been a result of maternal infection occurring later in gestation.
CONCLUSION: Although the incidence of intrauterine hydrops and fetal demise after maternal infection is low, there is a high rate of intrauterine viral infection that occurs throughout gestation and yields newborns who, although infected in utero, are asymptomatic at birth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655540     DOI: 10.1097/00006454-199806000-00011

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  11 in total

Review 1.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

2.  Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.

Authors:  J A Jordan; D Huff; J A DeLoia
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  Prenatal diagnosis of parvovirus B19-induced hydrops fetalis by chemiluminescence in situ hybridization.

Authors:  M Musiani; P Pasini; M Zerbini; G Gentilomi; A Roda; G Gallinella; E Manaresi; S Venturoli
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Induction of an embryonic mouse innate immune response following inoculation in utero with minute virus of mice.

Authors:  Irina Rostovsky; Claytus Davis
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

6.  Long term follow up of serostatus after maternofetal parvovirus B19 infection.

Authors:  J Dembinski; A M Eis-Hübinger; J Maar; R Schild; P Bartmann
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 7.  Exposure to fifth disease in pregnancy.

Authors:  Arthur Staroselsky; Chagit Klieger-Grossmann; Facundo Garcia-Bournissen; Gideon Koren
Journal:  Can Fam Physician       Date:  2009-12       Impact factor: 3.275

Review 8.  [Viral infections of the fetus and newborn infant].

Authors:  S Tremolada; S Delbue; P Ferrante
Journal:  Pediatr Med Chir       Date:  2008 Jul-Aug

9.  The prevalence of parvovirus B19 infection among pregnant women of Ardabil in 2013.

Authors:  Shahram Habibzadeh; Hadi Peeri-Doghaheh; Jafar Mohammad-Shahi; Elham Mobini; Samira Shahbazzadegan
Journal:  Iran J Microbiol       Date:  2016-06

Review 10.  Infection-Related Focal Segmental Glomerulosclerosis in Children.

Authors:  Anne Katrin Dettmar; Jun Oh
Journal:  Biomed Res Int       Date:  2016-05-17       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.